PATENT CLAIM ANALYSIS

Application Number: 15874476
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "003800"]

Abstract:
The present invention provides a CXCL12 1  peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Claim (Index 3):
The method of  claim 1 , wherein the autoimmune disease is selected from the group consisting of Multiple Sclerosis (MS), Guillain-Barre Syndrome, Amyotrophic Lateral Sclerosis, Parkinson's disease, Alzheimer's disease, Type I diabetes, lupus, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, early arthritis, reactive arthritis, osteoarthritis, ankylosing spondylitis, autoimmune uveitis, and inflammatory bowel diseases.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 86.0
- Lexical Diversity: 1.20513
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14736535', '13115666', '13502893', '12520811', '12255360']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7504748238489696
- 35 USC 102 Novelty (BERT): 0.5701634247469914
- Combined Prediction Score: 0.7324436839387718
- Mean Citation Score: 309.46267400000005
- Max Citation Score: 515.7698
- Similarity Product: 313.4787087840915

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test